Export financials
Processa Pharmaceuticals (PCSA)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

Processa Pharmaceuticals Income Statement 2025-2011 | PCSA
Brief overview of income trends at Processa Pharmaceuticals
This overview is based on financial performance over the past five years. The revenue attributed to Processa Pharmaceuticals moved from 20 thousand dollars to 5 thousand dollars between the two endpoints. The five-year change reached −75%, while CAGR stood at −24.2%. The negative rate indicates weakening core operations.
The gross result shifted from $20 thousand to $5 thousand, or −75%. Comparing the endpoints gives gross margins of 100% and 100%. Gross profitability remained broadly stable.
EBITDA changed from −1.1 million dollars to −71.4 thousand dollars (+93.6%). EBITDA grew faster than revenue, indicating positive operating leverage. Comparing the endpoints gives EBITDA margins of −5550% and −1427.3%. A wider margin confirms stronger operating efficiency.
Net income moved from −$940 thousand at the start to −$336 thousand at the end. The negative result improved without reaching break-even.
Conclusion
The results present an uneven picture without one dominant signal. The financial profile benefits from steady gross profitability, net-income growth and an improving EBITDA margin. The weaker side of the profile includes weak sales momentum and a narrow EBITDA buffer. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Processa Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
4.14 M | 387 K | 3.11 M | 371 K | 58.7 M | 35.2 M | 45.6 M | 119 M | 134 M | 1.66 M | 4.41 M | 19 M | - | - | - |
Shares |
1.31 M | 122 K | 1.31 M | 805 K | 15.3 M | 5.59 M | 5.53 M | 5.33 M | 4.66 M | 225 K | 225 K | 181 K | - | - | - |
Historical Prices |
3.16 | 3.16 | 2.37 | 0.46 | 3.83 | 11.4 | 9.75 | 18.2 | 21 | 7.4 | 19.6 | 106 | - | - | - |
Net Income |
-13.6 M | -11.9 M | -11.1 M | -27.4 M | -11.4 M | -14.4 M | -3.36 M | -3.77 M | -1.86 M | -336 K | -3.35 M | -4.53 M | -3.07 M | -2.44 M | -940 K |
Revenue |
- | - | - | - | - | - | - | - | - | 5 K | 113 K | 200 K | 312 K | 192 K | 20 K |
Gross Profit |
- | - | - | - | - | - | - | - | - | 5 K | -12.5 K | 87 K | 124 K | 58.9 K | 20 K |
Operating Income |
-14 M | -12.1 M | -11.5 M | -27.5 M | -12.1 M | -15.1 M | -3.94 M | -4.52 M | -1.8 M | -1.92 M | - | - | - | - | - |
Interest Expense |
- | - | - | - | 362 | 281 K | 36.7 K | 161 K | 59.1 K | 245 K | 236 K | 315 K | -110 K | -171 K | - |
EBITDA |
-14 M | -12.1 M | -11.5 M | -26.7 M | -12.1 M | -5.63 M | -3.13 M | -3.89 M | -1.8 M | -71.4 K | -748 K | -2.49 M | -2.55 M | -2.16 M | -1.11 M |
Operating Expenses |
14 M | 12.1 M | 11.5 M | 27.5 M | 12.1 M | 6.44 M | 3.94 M | 4.52 M | 1.8 M | 76.5 K | 975 K | 3.03 M | 3.09 M | 2.33 M | 790 K |
General and Administrative Expenses |
6.18 M | 4.78 M | 5.66 M | 8.76 M | 4.69 M | 3.26 M | 1.61 M | 1.44 M | 876 K | 70 K | 945 K | - | - | - | 610 K |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Processa Pharmaceuticals
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
2.97 M | 2.75 M | 2.62 M | 336 K | 1.9 M | 629 K | 374 K | 3.7 M | 3.28 M | 2.98 M | 2.47 M | 32.3 K | 1.35 M | 1.35 M | 1.14 M | -15.2 M | 16.2 M | 15.9 M | 15.8 M | 142 K | 15.5 M | 15.4 M | 14.6 M | 14.2 M | 5.59 M | 5.52 M | 5.52 M | -5.34 K | 5.53 M | 5.53 M | 5.53 M | -31.5 M | 38.7 M | 36.6 M | 35.3 M | 35.1 M | 31.7 M | 31.7 M | 11 M | 31.7 M | 11 M | 11 M | 11 M | 11 M | 11 M | 11 M | 11 M | 11 M | 8.43 M | 8.4 M | 8.26 M | 8.08 M | 7.84 M | 2.23 M | 1.9 M | - | 1.75 M | 1.75 M | - | - | - | - | - |
Net Income |
-183 M | -3.27 M | -3.38 M | -3.36 M | -3.44 M | -3.93 M | -2.83 M | - | -3.38 M | -3.01 M | -2.73 M | -2.4 M | -2.08 M | -2.61 M | -4.02 M | -13 M | -6.02 M | -5.16 M | -3.23 M | -3.18 M | -2.99 M | -3.16 M | -2.1 M | - | -3.07 M | -733 K | -874 K | -1.28 M | -864 K | -969 K | -751 K | - | -853 K | -1.21 M | -1.1 M | -634 K | -204 K | -53.6 K | -86.2 K | -102 K | -79.2 K | -53.9 K | -144 K | - | -296 K | -2.05 M | -645 K | - | -792 K | -851 K | -1.34 M | - | -719 K | -727 K | -816 K | - | -602 K | -475 K | - | - | - | - | - |
Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5 K | - | 5 K | 5 K | 5 K | - | 17.6 K | 32.8 K | 32.8 K | - | 16.6 K | 77 K | 7.44 K | - | 119 K | 96 K | 19.2 K | - | 48.6 K | 97 K | - | - | - | - | - |
Gross Profit |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5 K | - | 5 K | 5 K | 5 K | - | 15.5 K | 9.03 K | 12.8 K | - | 27.3 K | 42.6 K | 11.2 K | - | 45.5 K | 35.8 K | 7.08 K | - | 15.1 K | 43.2 K | - | - | - | - | - |
Operating Income |
-184 M | -2.34 M | -3.33 M | -3.7 M | -3.49 M | -3.95 M | -2.85 M | - | -3.42 M | -3.08 M | -2.81 M | -2.47 M | -2.17 M | -2.71 M | -4.11 M | -13.1 M | -6.06 M | -5.17 M | -3.23 M | -3.37 M | -3.11 M | -3.46 M | -2.19 M | - | -2.96 M | -802 K | -986 K | -912 K | -1 M | -1.14 M | -883 K | -742 K | -1.06 M | -1.43 M | -1.29 M | -575 K | -713 K | -280 K | -234 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | - | - | - | 71.7 K | - | - | - | 102 K | 83.5 K | - | - | 7.38 K | 1.58 K | - | - | 362 | 362 | - | 186 K | 19.3 K | 17.2 K | 26.7 K | -768 | 6.1 K | 4.6 K | 6.83 K | 8.32 K | 58.3 K | 87.7 K | 59.1 K | 44.2 K | 63.4 K | 61.9 K | 63.3 K | 63.3 K | 62.6 K | 56.1 K | - | 55 K | 47.7 K | 35.3 K | - | 130 K | 113 K | -60.1 K | - | -45.4 K | -33.8 K | -15.9 K | - | -34.7 K | -69.9 K | - | - | - | - | - |
EBITDA |
-184 M | -2.34 M | -3.33 M | -3.7 M | -3.49 M | -3.95 M | -2.85 M | - | -3.42 M | -3.08 M | -2.81 M | -2.47 M | -2.17 M | -2.71 M | -4.11 M | -12.9 M | -5.86 M | -4.97 M | -3.03 M | -3.17 M | -2.92 M | -3.26 M | -1.99 M | - | -2.95 M | -603 K | -787 K | -713 K | -805 K | -938 K | -684 K | -543 K | -863 K | -1.23 M | -1.29 M | -571 K | -716 K | -280 K | -234 K | - | 159 | 159 | 159 | - | 10.1 K | 23.9 K | 19.1 K | - | 22.4 K | 23.4 K | 21.8 K | - | 14.5 K | 13.2 K | 13 K | - | 4.68 K | 715 | - | - | - | - | - |
Operating Expenses |
- | - | 3.33 M | - | - | - | - | - | - | - | - | - | - | - | - | 13.1 M | 6.06 M | 5.17 M | 3.23 M | 3.37 M | 3.11 M | 3.46 M | 2.19 M | - | 2.96 M | 802 K | 986 K | 912 K | 1 M | 1.14 M | 883 K | 742 K | 1.06 M | 1.43 M | 1.29 M | 575 K | 713 K | 280 K | 13.7 K | -17.9 K | 4.97 K | 8.98 K | 80.5 K | - | 140 K | 1.89 M | 471 K | - | 689 K | 781 K | 1.3 M | - | 720 K | 729 K | 808 K | - | 583 K | 448 K | - | - | - | - | - |
General and Administrative Expenses |
4.29 M | 1.69 M | 1.52 M | 1.59 M | 1.83 M | 1.5 M | 1.26 M | - | 1.14 M | 1.35 M | 1.27 M | 1.15 M | 1.02 M | 1.03 M | 2.48 M | 2.63 M | 2.92 M | 2.03 M | 1.18 M | 1.3 M | 1.34 M | 1.33 M | 717 K | - | 423 K | 375 K | 484 K | 396 K | 419 K | 410 K | 398 K | 134 K | 451 K | 351 K | 470 K | 384 K | 255 K | 119 K | 13.6 K | -18.2 K | 4.4 K | 3.28 K | 80.5 K | - | 84.2 K | 362 K | 459 K | - | 677 K | 712 K | 805 K | - | 664 K | 666 K | 737 K | - | 519 K | 300 K | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Processa Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.